Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer By Ogkologos - August 17, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PSMAddition study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Cetuximab No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies MOST POPULAR Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor... March 26, 2024 Efficacy and Safety of Patritumab Deruxtecan in Patients with EGFR-mutated NSCLC... September 29, 2023 Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular... December 21, 2021 NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared... November 18, 2025 Load more HOT NEWS Encouraging Single-Agent Antitumour Activity of Divarasib Across KRAS G12C-positive Tumours Exercising While Living With Peripheral Neuropathy: What People Diagnosed With Cancer... Is That New Lump or Bump a Sarcoma? Anal Cancer Advances Open Door to Screening and Prevention
